Health Care [ 9/12 ] | Biotechnology [ 57/74 ]
NASDAQ | Common Stock
Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases.
The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies; and ProTECT, a tumor-specific immune co-stimulation platform.
Its lead product candidates include Ziihera (zanidatamab-hrii), a bispecific antibody targeting HER2-expressing tumors; zanidatamab for the treatment of neoadjuvant populations, breast cancer, and other HER2-expressing cancers; Pasritamig, a bispecific T cell engager targeting human kallikrein 2 for the treatment monotherapy and castration resistant prostate cancer; ZW191, a clinical- antibody-drug conjugates (ADC) that targets folate receptor alpha expressing tumors, including ovarian, endometrial, and non-small cell lung cancers; ZW251, a clinical-stage ADC molecule for the treatment of glypican 3 expressing hepatocellular carcinoma; ZW220, an ADC that targets NaPi2b-expressing NSCLC and ovarian cancer; ZW209, a novel TriTCE targeting Delta-like ligand 3 -expressing tumor cells for the treatment of solid tumors; and ZW1528, a bispecific molecule to treat chronic obstructive pulmonary disease.
It has strategic partnerships and collaborations with Jazz Pharmaceuticals plc; Bristol- Myers Squibb company; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Merck Sharp & Dohme Research GmbH; and Janssen Biotech, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 7, 26 | -0.59 Decreased by -96.67% | -0.10 Decreased by -490.00% |
| Mar 2, 26 | -0.55 Decreased by -77.42% | -0.32 Decreased by -70.60% |
| Nov 6, 25 | -0.26 Increased by +33.33% | -0.32 Increased by +18.75% |
| Aug 7, 25 | 0.03 Increased by +106.12% | -0.47 Increased by +106.38% |
| May 8, 25 | -0.30 Increased by +28.57% | -0.70 Increased by +57.14% |
| Mar 4, 25 | -0.31 Decreased by -55.00% | -0.09 Decreased by -236.23% |
| Oct 31, 24 | -0.39 Increased by +4.88% | -0.41 Increased by +4.88% |
| Aug 1, 24 | -0.49 Increased by +35.53% | -0.31 Decreased by -58.06% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 26 | 2.41 M Decreased by -91.12% | -44.16 M Decreased by -95.10% | Decreased by -1.83 K% Decreased by -2.10 K% |
| Dec 31, 25 | 2.52 M Decreased by -91.90% | -41.21 M Decreased by -75.31% | Decreased by -1.64 K% Decreased by -2.06 K% |
| Sep 30, 25 | 27.61 M Increased by +72.59% | -19.60 M Increased by +34.33% | Decreased by -70.99% Increased by +61.95% |
| Jun 30, 25 | 48.73 M Increased by +153.21% | 2.32 M Increased by +106.15% | Increased by +4.76% Increased by +102.43% |
| Mar 31, 25 | 27.11 M Increased by +170.29% | -22.64 M Increased by +28.49% | Decreased by -83.50% Increased by +73.54% |
| Dec 31, 24 | 31.03 M Increased by +83.33% | -23.51 M Decreased by -62.31% | Decreased by -75.75% Increased by +11.47% |
| Sep 30, 24 | 16.00 M Decreased by -3.07% | -29.85 M Decreased by -4.05% | Decreased by -186.56% Decreased by -7.34% |
| Jun 30, 24 | 19.24 M Increased by +174.82% | -37.69 M Increased by +26.33% | Decreased by -195.84% Increased by +73.19% |